Aakanksha TIWARI¹*, Rajesh KUMAR¹ and Alok KHANDURI²

¹Department of Veterinary Microbiology, CVASc., GBPUA and T, Pantnagar, Uttarakhand, India
²Department of Animal Husbandary, Uttarakhand State Government, Uttarakhand, India

*Corresponding Author: Aakanksha TIWARI, Department of Veterinary Microbiology, CVASc., GBPUA and T, Pantnagar, Uttarakhand, India.

Received: July 13, 2023; Published: September 10, 2023

Abstract

Egg-derived antibodies’ (IgY) preparation against a specific pathogen is an emerging technology for passive immunization. It is an efficient tool which can help to control the global problem of anti-microbial resistance. It is an effective therapeutic alternative having several advantages such as: non-invasive, cost-effective, large amount of IgY production at a single time, also IgY do not react with mammalian antibodies or rheumatoid factors, etc. The main principle behind IgY production is separation of the lipid component of the yolk from its water-soluble fraction. There are various methods described for the extraction of IgY from the egg-yolk like: Water dilution, Poly-ethylene glycol, Dextran sulphate, Ammonium sulphate, Xanthan sulphate, etc. These egg-derived antibodies find application in various fields like: immunodiagnostics, therapeutics, prophylactic, feed additive, etc. This review focuses on the production, importance, uses and applications of egg-derived antibodies.

Keywords: AMR; Egg-Derived Antibodies; IgY; Passive Immunization

References

1. Carbon C., et al. “Moving from recommendation to implementation and audit: Part I, Current recommendations and programsL: a critical commentary”. Clinical Microbiology and Infection 8 (2012): 92-106.
2. Raghunath D. Emerging antibiotic resistance in bacteria with special reference to India”. Journal of Biosciences 33 (2008): 593-603.
3. Thorpe KE., et al. “Antibiotic-resistant infection treatment costs have doubled since 2002 now exceeding $2 billion annually”. Health Affairs 37 (2018): 662-669.
4. Bandyopadhyay S and Samanta I. “Antimicrobial Resistance in Agri-Food Chain and Companion Animals as a Re-emerging Menace in Post-COVID Epoch: Low-and Middle-Income Countries Perspective and Mitigation Strategies”. Frontiers in Veterinary Science 7 (2020): 620.
5. World Health Organization (WHO) (2020).
6. Tan BKH and Vanitha J. “Immunomodulatory and antimicrobial effects of some traditional Chinese medicinal herbs: A review”. Current Medicinal Chemistry 11 (2004): 1423-1430.
7. Tiwari R., et al. “Bacteriophage therapy: A novel tool for combating bacterial diseases of poultry-A review”. Journal of Immunology and Immunopathology 13 (2011): 55-66.
8. Yegani M and Korver DR. “Application of egg yolk antibodies as replacement for antibiotics in poultry”. World Poultry 23 (2007): 22-25.
9. Owens “A ray of hope amid antibiotic gloom”. The Pharmaceutical Journal 297 (2007): 7893.
10. Chala G., et al. “A Review on: Antibody Engineering for Development of Therapeutic Antibodies”. International Journal of Immunology 3.3 (2015): 27-36.
11. Suay-García B and Pérez-Gracia MT. “The Antimicrobial Therapy of the Future: Combating Resistances”. Journal of Infectious Diseases and Therapy 2 (2014):
12. Khan UA., et al. “Antibacterial activity of some medicinal plants against selected human pathogenic bacteria”. European Journal of Microbiology and Immunology 4 (2013): 272-274.
13. Chanishvili N. “Phage therapy--history from Twort and d’Herelle through Soviet experience to current approaches”. Advances in Virus Research 83 (2012): 3-40.
14. Carillo CL., et al. “Bacteriophage therapy to reduce Campylobacter Jejuni colonization of Broiler chickens”. Applied and Environmental Microbiology 71 (2005): 6554-6563.
15. Morozova VV., et al. “Applications of Bacteriophages in the Treatment of Localized Infections in Humans”. Frontiers in Microbiology 9 (2018):
16. Eddleston M and Persson H. “Acute plant poisoning and antitoxin antibodies”. Journal of Toxicology: Clinical Toxicology 3 (2003): 309-315.
17. Han S., et al. “Effect of dietary supplementation with hyperimmunized hen egg yolk powder on diarrhoea incidence and intestinal health of weaned pigs”. Food and Agricultural Immunology 30.1 (2019): 333-348.
18. Szajewska H., et al. “Meta-analysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children”. Beneficial Microbes (2014).
19. Grehan MJ., et al. “Durable alteration of the colonic microbiota by the administration of donor fecal flora”. Journal of Clinical Gastroenterology 8 (2010): 551-561.
20. Yosef I., et al. “Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria”. Proceedings of the National Academy of Sciences of the United States of America 112 (2015): 7267-7272.
21. Hodyra-Stefaniak K., et al. “Mammalian Host- Versus-Phage immune response determines phage fate in vivo”. Scientific Reports 5 (2015): 1480.
22. O’ Neill J. “Vaccines and alternative approaches: Reducing our dependence on antimicrobials”. The Review on Antimicrobial Resistance (2016).
23. Peters BM., et al. “Antimicrobial peptides: primeval molecules or future drugs?” PLOS Pathogens 6 (2010): e1001067.
24. Jacobsen AS and Jenssen H. “Human cathelicidin LL-37 prevents bacterial biofilm formation”. Future Medicinal Chemistry 4 (2012): 1587-1599.
25. Haisma EM., et al. “LL-37- derived peptides eradicate multidrug-resistant Staphylococcus aureus from thermally wounded human skin equivalents”. Antimicrobial Agents and Chemotherapy 58 (2014): 4411-4419.
26. Hauram JS. “Recombinant polyclonal antibodies: the next generation of antibody therapeutics?” Drug Discovery Today 11 (2006): 13/14.
27. Maynard JA., et al. “Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity”. Nature Biotechnology 20 (2002): 597-601.
28. Chames P., et al. “Therapeutic antibodies: successes, limitations and hopes for the future”. British Journal of Pharmacology 157 (2009): 220-233.
29. Mine Y. “Egg bioscience and biotechnology”. Wiley-Interscience, Hoboken, NJ (2008).
30. Watanabe K., et al. “Binding activities of pronase-treated fragments from egg white ovomucin with anti-ovomucin antibodies and Newcastle disease virus”. Journal of Agricultural and Food Chemistry 46 (1998): 4501-4506.
31. Kovacs-Nolan J., et al. “Advances in the value of eggs and egg components for human health”. Journal of Agricultural and Food Chemistry 53 (2005): 8421-8431.
32. Li X., et al. “Effects of egg and yolk weights on yolk antibody production in laying chickens”. Poultry Science 77 (1997): 266-270.
33. Munhoz LS., et al. “Avian IgY antibodies: characteristics and applications in immunodiagnostic”. Ciência Rural, Santa Maria1 (2014)153-160.
34. Carlander DH., et al. “Peroral immunotherapy with yolk antibodies for the prevention on and treatment of enteric infections”. Immunologic Research 21 (2000): 1-6.
35. Spillner E., et al. “Avian IgY antibodies and their recombinant equivalents in research, diagnostics and therapy”. Biologicals5 (2012): 313-322.
36. Klemperer F. “Ueber natürliche immunität und ihre verwerthung für die immunisirungstherapie”. Archiv für die Experimentelle Pathologie und Pharmakologie 31 (1893): 356-382.
37. Hamal KR., et al. “Maternal antibody transfer from dams to their egg yolks, egg whites, and chicks in meat lines of chickens”. Poultry Science 85 (2006): 1364-
38. Gregory W. “IgY: Clues to the origins of modern antibodies”. Immunology Today 16 (1995): 392-398.
39. Tan SH., et al. “A novel, cost-effective and efficient chicken egg IgY purification procedure”. Journal of Immunological Methods 380 (2012): 73-76.
40. Akita EM and Nakai S. “Production and purification of Fab' fragments from chicken egg yolk immunoglobulin Y (IgY)”. Journal of Immunological Methods 162 (1993): 155.
41. Rahman S., et al. “Oral passive IgY-based immunotherapeutics: a novel solution for prevention and treatment of alimentary tract diseases”. Human Vaccines and Immunotherapeutics 9 (2013): 1039-
42. Wang LH., et al. “Characterization of chicken egg yolk immunoglobulins (IgYs) specific for the most prevalent capsular serotypes of mastitis causing Staphylococcus aureus”. Veterinary Microbiology 149 (2011): 415-
43. Jin LZ., et al. “In vitro inhibition of adhesion of enterotoxigenic Escherichia coli K88 to piglet intestinal mucus by egg-yolk antibodies”. FEMS Immunology and Medical Microbiology 21 (1998): 313-
44. Li X., et al. “Chicken egg yolk antibodies (IgY) as non-antibiotic production enhancers for use in swine production: a review”. Journal of Animal Science and Biotechnology 6 (2015): 40.
45. Akita EM and Nakai S. “Immunoglobulins from egg yolk: isolation and purification”. Journal of Food Science 57 (1992): 629-633.
46. Hatta H., et al. “A novel isolation method for hen egg yolk antibody, “IgY”. Agriculture and Biological Chemistry 54 (1990): 2531-2535.
47. 47.   Jensenius JC., et al. “Eggs: conveniently packaged antibodies. Methods for purification of yolk IgG”. Journal of Immunological Methods 46 (1981): 63-68.
48. Polson A., et al. “Improvements in the isolation of IgY from the yolks of eggs laid by immunized hens”. Immunological Investigations 14 (1985): 323-327.
49. Deignan T., et al. “Comparative Analysis of Methods of Purification of Egg Yolk Immunoglobulin”. Food and Agricultural Immunology1 (2000): 77-85.
50. Chang H., et al. “Isolation of immunoglobulin from egg yolk by anionic polysaccharides”. Journal of Agricultural and Food Chemistry 48 (2000): 995- 999.
51. Staak C., et al. “Isolation of IgY from Yolk. Chicken Egg Yolk Antibodies, Production and Application”. Springer-Verlag Berlin Heidelberg (2001).
52. Pereira E., et al. “Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review”. International Immunopharmacology 73 (2019): 293-303.
53. Kovacs-Nolan J and Mine Y. “Egg Yolk Antibodies for Passive Immunity”. Annual Review of Food Science and Technology 3 (2010): 163-182.

Citation

Citation: Aakanksha TIWARI., et al. “Egg-Derived Antibodies: An Effective Tool in Combating Anti-Microbial Resistance".Acta Scientific Veterinary Sciences 5.10 (2023): 21-28.

Copyright

Copyright: © 2023 Aakanksha TIWARI., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.